3/8/2021 12:11 PM
extends its wild rally; and ANAB falls on trial results. One stock on the New York Stock, % in the last week. Conversely, the shares of AnaptysBio Inc (NASDAQ:ANAB) are down 36.1% at $18.83, . Gapping to its lowest levels since October of 2020, ANAB is now contending with its 320-day moving average
9/22/2020 7:39 AM
, Inc. (NASDAQ: ANAB -- $15.81) engages in developing therapeutic product candidates for inflammation
11/8/2019 2:39 PM
The U.S. stock market is drifting lower to end the week, as Wall Street waits in limbo for any U.S.-China trade developments. Two stocks stocks making vastly different moves today are skin disease specialists AnaptysBio Inc (NASDAQ:ANAB) and Dermira Inc (NASDAQ:DERM). Here's a quick look at what's moving the shares of ANAB and DERM. ANAB In Nasdaq Cellar After "Surprising" Eczema Drug Failure, , and called out AnaptysBio for a lack of investor call for such an important event. ANAB earlier hit a record
11/8/2019 11:55 AM
for the first time since early August. AnaptysBio Inc (NASDAQ:ANAB) is the worst stock on the Nasdaq, to postpone a Phase 11 study for its asthma drug. What's more, both Wedbush and Guggenheim downgraded ANAB
3/27/2018 10:11 AM
Biotech stock AnaptysBio Inc (NASDAQ:ANAB) is trading higher today after the company reported positive mid-stage trial results for its experimental peanut allergy drug. ANAB shares were last seen up 0.3% at $114.21, but that's nothing new. The security has continued to push higher since its huge bull gap back in October, reaching a record high of $134 back on Feb. 20. Analysts continue, to improve going forward. Jefferies, which has a $145 price target for ANAB, says the trial update removes